Morgan Stanley has revised its rating on Dentsply Sirona (XRAY, Financial) from Overweight to Equal Weight, adjusting its price target from $21 to $14. This change reflects concerns over several challenges facing the company, including sluggish innovation, loss of market share, and exposure to tariff-related risks. Additionally, broader economic uncertainties and a challenging dental demand environment have contributed to the decision.
Despite its recent downturn—marked by a 21% decline in stock price this year, making it the poorest performer in its sector so far in 2024—Dentsply Sirona is perceived as having attractive current pricing. However, Morgan Stanley highlights the potential macroeconomic risks and tariff vulnerabilities that create an uncertain broader outlook for the company.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for Dentsply Sirona Inc (XRAY, Financial) is $19.25 with a high estimate of $27.00 and a low estimate of $15.00. The average target implies an upside of 47.17% from the current price of $13.08. More detailed estimate data can be found on the Dentsply Sirona Inc (XRAY) Forecast page.
Based on the consensus recommendation from 17 brokerage firms, Dentsply Sirona Inc's (XRAY, Financial) average brokerage recommendation is currently 2.6, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Dentsply Sirona Inc (XRAY, Financial) in one year is $32.31, suggesting a upside of 147.02% from the current price of $13.08. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Dentsply Sirona Inc (XRAY) Summary page.
